# MVT-100 Manufacturing and Commercialization.

> **NIH NIH SB1** · MICROVASCULAR THERAPEUTICS, LLC · 2023 · $206,081

## Abstract

PROJECT SUMMARY / ABSTRACT
This Commercialization Readiness Program, CRP, (SB1) proposal is directed towards the commercialization of
the MVT-100 product as funded by the parent SBIR Phase II grant (NHLBI Phase II SBIR, R44HL137447-01).
This CRP will fund finalization of the Quality system to support commercialization and scale-up manufacturing
suitable for initial product launch as well as finalization of regulatory strategy to yield commercially viable label
claims for MVT-100.
This specific proposal is directed towards development of Microvascular Therapeutics’ new, patented, improved,
electrostatically neutral, MB USCA, MVT-100, which will firstly be developed for echocardiography via the
accelerated 505(b)(2) pathway for development as designated by the FDA. Definity® is an anionic MB (net
negative charge) and requires refrigerated storage while MVT-100 is designed for room temperature storage.
Our goals are to develop and fully implement a Quality System with upscale manufacturing of our product that
will be approved for echocardiography, subsequently developed for radiology ultrasound imaging, and as a
platform for therapeutic/theranostic applications.
Thus, the Specific Aims are as follows: 1) To finalize and implement a Quality System Control. The goal is to
have a Quality System Control in place and ready for full upscale manufacturing of MVT-100. 2) To develop and
optimize industrial production methods necessary to ensure consistent and controlled scale-up GMP
manufacturing of MVT-100. Milestones are to obtain consistent and controlled scale-up manufacturing
processes. And finally, 3) To finalize our regulatory strategy and obtain technical assistance for market research.
We will obtain a defined regulatory strategy with a ready-to-launch vision for MVT-100.
Successful completion of the proposed aims and subsequent pivotal study will result in a new, room temperature
stable MB for echocardiography yielding not only an improved product for echocardiography with less bioeffects
but also a platform for development of radiology, molecular imaging and theranostic products. After MVT-100 is
approved for echocardiography, and with commercial scale manufacturing in place, our plan is to raise additional
capital to build a sales force and launch the product.

## Key facts

- **NIH application ID:** 10596070
- **Project number:** 5SB1HL137447-04
- **Recipient organization:** MICROVASCULAR THERAPEUTICS, LLC
- **Principal Investigator:** Wyatt Daniel Unger
- **Activity code:** SB1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $206,081
- **Award type:** 5
- **Project period:** 2017-08-17 → 2024-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10596070

## Citation

> US National Institutes of Health, RePORTER application 10596070, MVT-100 Manufacturing and Commercialization. (5SB1HL137447-04). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10596070. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*